Research programme: TRPV1 antagonists - Eli LillyAlternative Names: Transient receptor potential vanilloid subtype-1 antagonists - Eli Lilly; VR1 antagonists - Eli Lilly
Latest Information Update: 24 Mar 2009
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Mechanism of Action TRPV1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation; Pain; Urinary incontinence
Most Recent Events
- 30 Oct 2007 Preclinical trials in Urinary incontinence in USA (unspecified route)
- 30 Oct 2007 Preclinical trials in Pain in USA (unspecified route)
- 30 Oct 2007 Preclinical trials in Inflammation in USA (unspecified route)